Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rebecca L Elstrom

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Current Hematologic Malignancy Reports|April 29, 2010
FDG-PET scans in patients with lymphomaRebecca L Elstrom, John P Leonard
Hematology/Oncology Clinics of North America|October 29, 2008
New biologic agents and immunologic strategiesRebecca L Elstrom, Peter Martin, John P Leonard
European Journal of Immunology|July 29, 2003
Activated Akt promotes increased resting T cell size, CD28-independent T cell growth, and development of autoimmunity and lymphomaJeffrey C Rathmell, Rebecca L Elstrom, Ryan M Cinalli, et al.
Hematology (Amsterdam, Netherlands)|April 18, 2012
Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimenMorton Coleman, Gia Ruan, Rebecca L Elstrom, et al.
Clinical Lymphoma|July 13, 2004
Enhanced marrow [18F]fluorodeoxyglucose uptake related to myeloid hyperplasia in Hodgkin's lymphoma can simulate lymphoma involvement in marrowRebecca L Elstrom, Donald E Tsai, Jo-Anne Vergilio, et al.
Oncogene|April 5, 2005
The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidationMonica Buzzai, Daniel E Bauer, Russell G Jones, et al.
Leukemia & Lymphoma|January 24, 2012
Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphomaRebecca L Elstrom, Biree Andemariam, Peter Martin, et al.
Immunity|July 18, 2002
The CD28 signaling pathway regulates glucose metabolismKenneth A Frauwirth, James L Riley, Marian H Harris, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 1, 2010
Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategiesRebecca L Elstrom, Peter Martin, Katya Ostrow, et al.
Cancer Research|June 3, 2004
Akt stimulates aerobic glycolysis in cancer cellsRebecca L Elstrom, Daniel E Bauer, Monica Buzzai, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Current Hematologic Malignancy Reports|April 29, 2010
FDG-PET scans in patients with lymphomaRebecca L Elstrom, John P Leonard
Hematology/Oncology Clinics of North America|October 29, 2008
New biologic agents and immunologic strategiesRebecca L Elstrom, Peter Martin, John P Leonard
European Journal of Immunology|July 29, 2003
Activated Akt promotes increased resting T cell size, CD28-independent T cell growth, and development of autoimmunity and lymphomaJeffrey C Rathmell, Rebecca L Elstrom, Ryan M Cinalli, et al.
Hematology (Amsterdam, Netherlands)|April 18, 2012
Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimenMorton Coleman, Gia Ruan, Rebecca L Elstrom, et al.
Clinical Lymphoma|July 13, 2004
Enhanced marrow [18F]fluorodeoxyglucose uptake related to myeloid hyperplasia in Hodgkin's lymphoma can simulate lymphoma involvement in marrowRebecca L Elstrom, Donald E Tsai, Jo-Anne Vergilio, et al.
Oncogene|April 5, 2005
The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidationMonica Buzzai, Daniel E Bauer, Russell G Jones, et al.
Leukemia & Lymphoma|January 24, 2012
Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphomaRebecca L Elstrom, Biree Andemariam, Peter Martin, et al.
Immunity|July 18, 2002
The CD28 signaling pathway regulates glucose metabolismKenneth A Frauwirth, James L Riley, Marian H Harris, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 1, 2010
Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategiesRebecca L Elstrom, Peter Martin, Katya Ostrow, et al.
Cancer Research|June 3, 2004
Akt stimulates aerobic glycolysis in cancer cellsRebecca L Elstrom, Daniel E Bauer, Monica Buzzai, et al.
Pageof 2